



## MONOCLONAL ANTIBODY

For research use only. Not for clinical diagnosis

**Catalog No. CEC-050**

### Anti-Septin9 isoform3

#### BACKGROUND

The septin GTPases family have several roles during cell division, cytoskeletal organization and membrane-remodeling events. Septin 9, a member of the septin family, has several splicing variants and has been reported to be highly expressed in some cancer cells.

<b>Product type</b>	Primary antibody
<b>Immunogen</b>	Synthetic peptide corresponding to the N-terminus region (aa 1-11) of rat Septin9 isoform3, MERDRITALKRC
<b>Host</b>	Rat
<b>Clone number</b>	1A6C2
<b>Isotype</b>	IgG2a, $\kappa$
<b>Source</b>	Culture supernatant
<b>Purification</b>	Ion-exchange chromatography
<b>Form</b>	Liquid
<b>Presentation</b>	Purified monoclonal antibody in PBS, 50% Glycerol, 0.05%w/v ProClin300
<b>Concentration</b>	1 mg/mL
<b>Volume</b>	100 $\mu$ L
<b>Label</b>	Unlabeled
<b>Specificity</b>	Septin9 variant3
<b>Cross reactivity</b>	Human, Monkey, Mouse, Rat      Other species have not been tested.
<b>Storage</b>	Store below -20°C (below -70°C for prolonged storage) Aliquot to avoid cycles of freeze/thaw.
<b>Other</b>	-

#### Application notes

##### Recommended use

WB, ICC, IHC      Not tested for other applications.

##### Recommended dilutions

Western blotting, 1/1,000 to 1/5,000

Immunocytochemistry, 1/100 to 1/500


Immunohistochemistry: 1/100 to 1/500

Optimal dilutions/concentrations should be determined by the end user.

#### References


- 1) TOXICOLOGICAL SCIENCES ,(2011) 119: 61–72.
  - 2) Breast Cancer Research, (2011) 13:R76
  - 3) Scientific Reports. (2017); 7: 44976.
- This antibody is used in ref.1, 2 and 3.

## ANTIBODY CHARACTERIZATION



HeLa cell

**Fig.1 Immunohistochemistry - Septin9 isoform3 (1A6C2) , HeLa cell**



**Fig.2 Western blot - Septin9 isoform3 (1A6C2) , HeLa cell total extract**

## SEPTINE 9: isoforms

		1					50					100
Septin	9_v1	MKKSYSGGTR	TSSGRLRLRG	DSSGPAALKRS	FEVEEVEVTPN	STPPRRVQTP	LLRATVASST	QKFQDLGVKN	SEPSARHVDS	LSQRSFKASL	RRVELSGPKA	
Septin	9_v2	.....MSDP	AVNAQLDGI	ISDFEALKRS	FEVEEVEVTPN	STPPRRVQTP	LLRATVASST	QKFQDLGVKN	SEPSARHVDS	LSQRSFKASL	RRVELSGPKA	
Septin	9_v3	.....	.....ME	RDRISALKRS	FEVEEVEVTPN	STPPRRVQTP	LLRATVASST	QKFQDLGVKN	SEPSARHVDS	LSQRSFKASL	RRVELSGPKA	
Septin	9_v4	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Septin	9_v5	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
		101					150					200
Septin	9_v1	AEFVSRRTTEL	SIDISSKQVE	NAGAIGPSRF	GLKRAEVLGH	KTPEPAPRRT	EITIVKPQES	AHRRMEPPAS	KVPEVPTAPA	TDAAPKRVEI	QMPKPAAEPT	
Septin	9_v2	AEFVSRRTTEL	SIDISSKQVE	NAGAIGPSRF	GLKRAEVLGH	KTPEPAPRRT	EITIVKPQES	AHRRMEPPAS	KVPEVPTAPA	TDAAPKRVEI	QMPKPAAEPT	
Septin	9_v3	AEFVSRRTTEL	SIDISSKQVE	NAGAIGPSRF	GLKRAEVLGH	KTPEPAPRRT	EITIVKPQES	AHRRMEPPAS	KVPEVPTAPA	TDAAPKRVEI	QMPKPAAEPT	
Septin	9_v4	.....	.....	.....	.....	.....	.....	.....MEPPAS	KVPEVPTAPA	TDAAPKRVEI	QMPKPAAEPT	
Septin	9_v5	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
		201					250					300
Septin	9_v1	APSPAQTLEN	SEPAPVSQLQ	SRLEPKQPFP	VAEATPRSQE	ATEAAPSCVG	DMADTPRDAG	LKQAPASRNE	KAPVDFGYVG	IDSILEQMRR	KAMKQGFEPN	
Septin	9_v2	APSPAQTLEN	SEPAPVSQLQ	SRLEPKQPFP	VAEATPRSQE	ATEAAPSCVG	DMADTPRDAG	LKQAPASRNE	KAPVDFGYVG	IDSILEQMRR	KAMKQGFEPN	
Septin	9_v3	APSPAQTLEN	SEPAPVSQLQ	SRLEPKQPFP	VAEATPRSQE	ATEAAPSCVG	DMADTPRDAG	LKQAPASRNE	KAPVDFGYVG	IDSILEQMRR	KAMKQGFEPN	
Septin	9_v4	APSPAQTLEN	SEPAPVSQLQ	SRLEPKQPFP	VAEATPRSQE	ATEAAPSCVG	DMADTPRDAG	LKQAPASRNE	KAPVDFGYVG	IDSILEQMRR	KAMKQGFEPN	
Septin	9_v5	.....	.....	.....	.....	.....	DMADTPRDAG	LKQAPASRNE	KAPVDFGYVG	IDSILEQMRR	KAMKQGFEPN	
		301					350					400
Septin	9_v1	IMVVQSGSLG	KSTLINTLFK	SKISRKSQVP	TSEERIPKTI	EIKSITHDIE	EKGVRMMLTV	IDTPGFGDHI	NNENCWQPM	KFINDQYEKY	LQEEVNINRK	
Septin	9_v2	IMVVQSGSLG	KSTLINTLFK	SKISRKSQVP	TSEERIPKTI	EIKSITHDIE	EKGVRMMLTV	IDTPGFGDHI	NNENCWQPM	KFINDQYEKY	LQEEVNINRK	
Septin	9_v3	IMVVQSGSLG	KSTLINTLFK	SKISRKSQVP	TSEERIPKTI	EIKSITHDIE	EKGVRMMLTV	IDTPGFGDHI	NNENCWQPM	KFINDQYEKY	LQEEVNINRK	
Septin	9_v4	IMVVQSGSLG	KSTLINTLFK	SKISRKSQVP	TSEERIPKTI	EIKSITHDIE	EKGVRMMLTV	IDTPGFGDHI	NNENCWQPM	KFINDQYEKY	LQEEVNINRK	
Septin	9_v5	IMVVQSGSLG	KSTLINTLFK	SKISRKSQVP	TSEERIPKTI	EIKSITHDIE	EKGVRMMLTV	IDTPGFGDHI	NNENCWQPM	KFINDQYEKY	LQEEVNINRK	
		401					450					500
Septin	9_v1	KRIPDTRVHC	CLYFIPATGH	SLRPLDIEFM	KRLSKVVNIV	PVIAKADTLT	LEERVHFKQR	ITADLLSNGI	DVYPQKEFDE	DSEDRLVNEK	FREMIFFAVV	
Septin	9_v2	KRIPDTRVHC	CLYFIPATGH	SLRPLDIEFM	KRLSKVVNIV	PVIAKADTLT	LEERVHFKQR	ITADLLSNGI	DVYPQKEFDE	DSEDRLVNEK	FREMIFFAVV	
Septin	9_v3	KRIPDTRVHC	CLYFIPATGH	SLRPLDIEFM	KRLSKVVNIV	PVIAKADTLT	LEERVHFKQR	ITADLLSNGI	DVYPQKEFDE	DSEDRLVNEK	FREMIFFAVV	
Septin	9_v4	KRIPDTRVHC	CLYFIPATGH	SLRPLDIEFM	KRLSKVVNIV	PVIAKADTLT	LEERVHFKQR	ITADLLSNGI	DVYPQKEFDE	DSEDRLVNEK	FREMIFFAVV	
Septin	9_v5	KRIPDTRVHC	CLYFIPATGH	SLRPLDIEFM	KRLSKVVNIV	PVIAKADTLT	LEERVHFKQR	ITADLLSNGI	DVYPQKEFDE	DSEDRLVNEK	FREMIFFAVV	
		501					550			586		
Septin	9_v1	GSDHEYQVNG	KRILGRKTKW	GTIEVENTTH	CEFAYLRDLL	IRTHMQNIKD	ITSSIHFEAY	RVKRLNEGSS	AMANGVEEKE	PEAPEM		
Septin	9_v2	GSDHEYQVNG	KRILGRKTKW	GTIEVENTTH	CEFAYLRDLL	IRTHMQNIKD	ITSSIHFEAY	RVKRLNEGSS	AMANGVEEKE	PEAPEM		
Septin	9_v3	GSDHEYQVNG	KRILGRKTKW	GTIEVENTTH	CEFAYLRDLL	IRTHMQNIKD	ITSSIHFEAY	RVKRLNEGSS	AMANGVEEKE	PEAPEM		
Septin	9_v4	GSDHEYQVNG	KRILGRKTKW	GTIEVENTTH	CEFAYLRDLL	IRTHMQNIKD	ITSSIHFEAY	RVKRLNEGSS	AMANGVEEKE	PEAPEM		
Septin	9_v5	GSDHEYQVNG	KRILGRKTKW	GTIEVENTTH	CEFAYLRDLL	IRTHMQNIKD	ITSSIHFEAY	RVKRLNEGSS	AMANGVEEKE	PEAPEM		

*For research use only. Not for diagnostic use.*



COSMO BIO CO., LTD.

【JAPAN】

TOYO EKIMAE BLDG. 2-20, TOYO 2-CHOME,  
KOTO-KU. TOKYO 135-0016, JAPAN  
Phone: +81-3-5632-9610  
FAX: +81-3-5632-9619  
URL: <https://www.cosmobio.co.jp/>



Cosmo Bio USA

【Outside Japan】

2792 Loker Ave West, Suite 101  
Carlsbad, CA 92010, USA  
email: [info@cosmobiousa.com](mailto:info@cosmobiousa.com)  
Phone/FAX: (+1) 760-431-4600  
URL: [www.cosmobiousa.com](http://www.cosmobiousa.com)